Stock Events

Stock Events

Orgenesis 

0
27
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 11Expected
Q4 2025
Next
2.17
2.5
2.83
3.17
Expected EPS
N/A
Actual EPS
N/A

Financials

-7,527.7%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
666,673.2Revenue
-50.19MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 45O0.STU. It's not an investment recommendation.
NVIDIA
4
NVDA
Apple
3
AAPL
Microsoft
3
MSFT
Realty Income
3
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is involved in gene editing, a direct competitor to Orgenesis's cell and gene therapy technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is a leading gene editing company using CRISPR/Cas9 technology, competing in the gene therapy sector.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine operates in the CRISPR gene editing space, making it a direct competitor to Orgenesis's gene therapy efforts.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a growing portfolio in gene therapy, making it a competitor to Orgenesis, especially in commercialization and development.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and has ventured into gene therapy, competing with Orgenesis.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space, particularly in cancer, which is a focus for Orgenesis.

About

Orgenesis Inc. is a global biotechnology firm dedicated to the field of cell and gene therapies. The company has engineered an innovative Point of Care (POCare) platform. This system incorporates a portfolio of licensed POCare therapeutics, which are manufactured and prepared using automated, self-contained POCare technology within a cooperative network. Orgenesis primarily concentrates on autologous therapies, developing customized processes and systems for each treatment. These utilize a closed, automated processing methodology, validated for safe and compliant production directly at the patient's location, facilitating immediate therapeutic application. Established in 2008 as Business Outsourcing Service, Inc., the company adopted the name Orgenesis Inc. in August 2011 and is headquartered in Germantown, Maryland.
Show More
CEO
Vered Caplan
Employees
77
Country
United States
ISIN
US68619K3032
WKN
000A40PUK

Listings

STU
DE
45O0.STU
OTC Link
US
ORGS

0 Comments

Share your thoughts

FAQs

What is Orgenesis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Orgenesis stocks are traded under the ticker 45O0.STU.
When is the next Orgenesis earnings date?▼
Orgenesis is going to release the next earnings report on November 11, 2026.
What is Orgenesis revenue for the last year?▼
Orgenesis revenue for the last year amounts to 666,673.2 EUR.
What is Orgenesis net income for the last year?▼
45O0.STU net income for the last year is -50.19M EUR.
How many employees does Orgenesis have?▼
As of November 3, 2026, the company has 77 employees.
In which sector is Orgenesis located?▼
Orgenesis operates in the Health & Wellness sector.
When did Orgenesis complete a stock split?▼
The last stock split for Orgenesis was on September 25, 2024 with a ratio of 1:10.
Where is Orgenesis headquartered?▼
Orgenesis is headquartered in Germantown, United States.